Pheniramine induced supraventricular tachycardia resistant to adenosine: A case report and review

• Published in: Annals of medicine and surgery 2022-06, Vol.78, p.103621, Article 103621
• Main Authors: Mohamud, Mohamed Farah Yusuf, Waberi, Mohamud Mire
• Format: Article
• Language: English
• Subjects: Adenosine; Arrhythmia; Case Report; Diltiazam; Pheniramine; Supraventricular tachycardia
• ISSN: 2049-0801; 2049-0801
• DOI: 10.1016/j.amsu.2022.103621

Cardiac toxicity is a very seldom documented side effect of Pheniramine. Although second-generation antihistamines such as terfenadine and astemizole have been linked to cardiac injury, the incidence of SVT after Pheniramine treatment on adult clinical dose is currently unknown. In this case, we present a 22-year-old girl who developed adenosine-resistant supraventricular tachycardia (SVT) after being given pheniramine due to a bean allergy. It is crucial to know that symptomatic SVT could occur with therapeutic doses of pheniramine. This case highlights the importance of a comprehensive drug evaluation in emergency situations to identify the underlying etiologies and prompt treatment commencement. It also emphasizes the significance of assessing and choosing acute drugs for each patient admitted to the emergency unit to ensure the start of a newer medication if necessary. •Thromboembolism is the third most common cardiovascular disorders and substantial worldwide health burden, with 1 to 2 instances per 1000 persons each year.•The incidence of cardiovascular thromboembolic among COVID19 infected patients is relatively high, and it is associated with elder (>65years), IHD, diabetes and chronic liver disease. There was significant statistical difference in the proportion of examinees with thrombotic and non-thrombotic events in relation to outcome (p=0.000).•In our knowledge there is no study explored the role of incidence, risk factors and outcome of thromboembolic diseases among patients with SARSCoV-2 infection in Somalia. Similarly, limited data are currently available about the incidence of thromboembolic in Sub-Sahara African countries. This study aimed to describe theepidemiological characteristics, clinical relevance, risk factor and outcome of cardiovascular thromboembolic complications among COVID-19 infected patients.